⌘K
OverviewStock screenerAnalyst actionsTicker roomsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqCM

VKTX

Viking Therapeutics, Inc.

Healthcare · Biotechnology

24.40USD

-1.4300 (-5.54%)

Alert
DescriptionHistoricalFinancialsRelative ValueResearchNewsCommunityRoomOptionsPrice Chart ↗Fundamental Chart ↗
ProfileRatiosRevenue & EPS
Reading financial statements from SEC filings…
A first visit to a security takes a few seconds.

Community sentiment

Not enough data yet

A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.

Sign in to share your take on VKTX.

Members' own stated views, weighted by account age and track record on this site (simulated portfolios and calls). Not a forecast or a price signal. How this is worked out
  • Only members whose accounts are at least 14 days old and who have a track record on this site (simulated portfolios and calls) count, and bots never do. A take from anyone else is saved and starts to count the day they qualify.
  • A take fades: it counts half as much after 7 days and drops out after 30.
  • Members with a strong record count more. Everyone else counts together for a capped share, so many accounts cannot outweigh a few strong ones.
  • Nothing is shown until 5 qualifying members have taken part, 2 of them with a strong record. It stays an early read until 3 have one and the sample is large enough.
  • Until 20 members have taken part the marker only says bullish, bearish or mixed, at a fixed spot, and the number of members is given as a band, not a count.
  • The reading is refreshed about every 30 minutes, so a take you have just made will not move it straight away.
  • Your own take is private: only the totals are shown, and never who said what.
1)

Comparable Revenue

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY0.00.00.00.00.00.0
Q10.00.00.00.00.0—
Q20.00.00.00.00.0—
Q30.00.00.00.00.0—
Q40.0*0.0*0.0*0.0*0.0—
2)

Comparable Earnings Per Share

EM »

Revenue

 

 

QuarterlyAnnual
Reported
(USD)202220232024202520262027
FY-.900-.910-1.01-3.19-4.59-4.34
Q1-.210-.250-.260-.410-1.37—
Q2-.230-.190-.200-.580-1.10—
Q3-.210-.230-.220-.810-1.06—
Q4-.255*

Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.

3)

Revenue to Profit Conversion

Revenue to net income

 

 

QuarterlyAnnual
Level
-.261*
-.325*
-1.40*
-1.09
—
4)

Debt Level and Coverage

Debt level and coverage

 

 

QuarterlyAnnual
Debt